ImmunityBio partners with Rafa to commercialize ANKTIVA in Israel
IBRX•ImmunityBio named Rafa Laboratories its exclusive commercialization partner for ANKTIVA in Israel. Israel authorized ANKTIVA with BCG for adults with BCG-unresponsive NMIBC with carcinoma in situ; approval followed submission by four months, and a registration license is expected within weeks.
1. Israel authorization
ImmunityBio partnered with Rafa Laboratories as the exclusive commercialization partner for ANKTIVA in Israel under a distribution agreement. Israel authorized ANKTIVA with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The approval came four months after submission under accelerated review, and the registration license is expected within weeks. ANKTIVA is now authorized in 35 countries.
